Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
Antiplatelet agents are the medications of choice for preventing non-cardioembolic strokes. The diverse pathways involved in platelet function suggest the possibility of synergistic effects by combining various agents. In heart disease and in the setting of coronary artery stents, antiplatelet therapy with clopidogrel and aspirin has established benefits. Although it is tempting to extrapolate the benefits of this combination for stroke prevention, recent clinical trials have not borne this out. Unacceptable bleeding risks without additional efficacy weigh against the routine use of clopidogrel with aspirin for stroke prophylaxis. The combination of aspirin and extended-release dipyridamole has demonstrated superiority over aspirin in two large secondary stroke prevention trials.
Schwartz
Neil E
NE
Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford University, 701 Welch Road, #B325, Palo Alto, CA 94304, USA. neuro1@stanford.edu
Albers
Gregory W
GW
D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D000077144:Clopidogrel; D004176:Dipyridamole / Q000008:administration & dosage / Q000009:adverse effects; D004347:Drug Interactions / Q000502:physiology; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D018570:Risk Assessment; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin